

Vaccine introduction grants and operational support for campaigns


Aurélia Nguyen

*GAVI Alliance Board meeting
Washington, DC, USA, 12-13 June 2012*



Background: Vaccine introduction grants

- Until March 2012, GAVI had disbursed ~ 150 vaccine introduction grants (US\$ 28.6m total).



Objective, scope and operating guidelines

- **Objective**

- Facilitate timely, effective implementation of critical activities:
 - Before new vaccine introductions
 - For delivery during campaigns
- One-time investments, covering a share of the cost


- **Scope**

- All new GAVI-supported vaccines
- Activities driven by country needs
- Does not cover recurrent costs

- **Operating guidelines**


- Flexible, timely, simple, separate from other cash support, not used for co-financing

Recommended policy: what has changed?



GAVI Alliance Board meeting
12-13 June 2012

Recommended policy: what has changed?



GAVI Alliance Board meeting
12-13 June 2012

Recommended policy: funding levels

1. Vaccine introduction grants:

- Vaccines delivered to infants: **US\$ 0.80 per child** in birth cohort (min. US\$ 100,000)
- HPV vaccines delivered to adolescent girls: **US\$ 2.40 per girl** in target population (min. US\$ 100,000)

2. Operational support for campaigns:

- **US\$ 0.65 per individual** in target population


3. Product switches after first introduction:

- **One third of full grant** for transition to new product, provided criteria are met

Implementation

- Effective date: September 2012
- TAP applies, mandatory audits for grants >US\$ 250k
- Policy updates:
 - Every 2 years: funding levels, financial management requirements
 - 2017: full policy review
- Enabling factors:
 - Enhanced financial and technical support from GAVI Alliance partners
 - Improved knowledge base on actual costs and financing

Projected financial implications for GAVI*



- Total projected **incremental** cost to GAVI for 2012-2015 **US\$ 262m**, of which:
 - US\$ 65m for vaccine introduction grants (154 grants)
 - US\$192m for operational support for campaigns (55 campaigns)
 - US\$6m for product switches

* Based on SDFv.5, excluding India; red bars include routine introductions of MR vaccines after GAVI supported campaigns

Projected financial implications for GAVI

- US\$ 61m additional cost for already approved proposals introducing after Sept 2012
- 5.4% of projected GAVI expenditures (2.4% under current policy) 2012–2020
- Cash support closely linked to immunisation outcomes
- Fits within 15%–25% target for cash support

Recommendations to the GAVI Board

- The Programme and Policy Committee (PPC) recommends that the GAVI Alliance Board:
 - **Approves** the GAVI vaccine introduction grant and operational support for campaigns policy (the “**Policy**”), as described in Annex 1 of Doc 13;
 - **Requests** the Secretariat to make the necessary arrangements to ensure that vaccine introductions and campaigns occurring on or after 1 September 2012 benefit from the Policy regardless of when the country proposal was approved.



www.gavialliance.org